Cheminformatic Tools and Databases for Pharmacology

session 67056 - Total of 2 hits - Display   hits per page:

Add another drug(s) by one keyword:
Exemple: “nib“ and click on the Search button (do not press Enter on the keyboard)

1 INNClassRoute (list)PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)Primary Target and PDB code of Protein-Drug complexTargets from DrugCentral Links
ENZALUTAMIDE (has an active metabolite)

ENZALUTAMIDE


ATC L02BB04

ANTINEOPLASTIC
ANDROGEN RECEPTOR INHIBITOR
TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
DECREASED PROLIFERATION AND INDUCED CELL DEATH

ORAL

Cmax 35.7 MICROMOLAR

VD 110 LITER

PPB 97 PERCENT

Cl 0.56 LITER / HOUR

HT 139 HOUR

SOLUBILITY PRACTICALLY INSOLUBLE IN WATER

ANDROGEN RECEPTOR (AR)

ANDROGEN RECEPTOR ANTAGONIST CHEMBL1871 ANDROGEN RECEPTOR P10275 ANDROGEN RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C4ANSM (in French)

Dailymed
Drugs.com

SIDER side effects

Chemical Probes Portal

ChEMBL
BindingDB
DrugBank

2 INNClassRoute (list)PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)Primary Target and PDB code of Protein-Drug complexTargets from DrugCentral Links
M ENZALUTAMIDE (is an active metabolite)

ENZALUTAMIDE


ATC L02BB04

ANTINEOPLASTIC
ANDROGEN RECEPTOR INHIBITOR
TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
DECREASED PROLIFERATION AND INDUCED CELL DEATH

-

Cmax 28.2 MICROMOLAR

VD 288 LITER (EQN)

PPB 95 PERCENT

Cl 1.02 LITER / HOUR

HT 196 HOUR

ANDROGEN RECEPTOR (AR)

ANDROGEN RECEPTOR ANTAGONIST CHEMBL1871 ANDROGEN RECEPTOR P10275 ANDROGEN RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C4ANSM (in French)

Dailymed
Drugs.com

SIDER side effects

Chemical Probes Portal

ChEMBL
BindingDB
DrugBank



Copyright © 2019 Université Côte d'Azur CNRS - All rights reserved
  | Contact |